Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix seeks FDA OK for abuse-deterrent Zohydro

This article was originally published in Scrip

Executive Summary

Zogenix held true to its word that it would seek the FDA's approval by October for an abuse-deterrent formulation of Zohydro, the company's single-entity extended-release hydrocodone, disclosing on the first day of the month it had submitted a supplemental new drug application (sNDA) to the agency.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC026522

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel